Protéines de liaison au TGF-bêta latent : Questions médicales fréquentes
Nom anglais: Latent TGF-beta Binding Proteins
Descriptor UI:D053779
Tree Number:D12.776.860.300.688
Termes MeSH sélectionnés :
Cell Line
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines de liaison au TGF-bêta latent : Questions médicales les plus fréquentes",
"headline": "Protéines de liaison au TGF-bêta latent : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines de liaison au TGF-bêta latent : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-18",
"dateModified": "2025-04-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines de liaison au TGF-bêta latent"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines de la matrice extracellulaire",
"url": "https://questionsmedicales.fr/mesh/D016326",
"about": {
"@type": "MedicalCondition",
"name": "Protéines de la matrice extracellulaire",
"code": {
"@type": "MedicalCode",
"code": "D016326",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.860.300"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéines de liaison au TGF-bêta latent",
"alternateName": "Latent TGF-beta Binding Proteins",
"code": {
"@type": "MedicalCode",
"code": "D053779",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Nalani Sachan",
"url": "https://questionsmedicales.fr/author/Nalani%20Sachan",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell Biology, NYU Grossman School of Medicine, New York, New York, USA."
}
},
{
"@type": "Person",
"name": "Hui Liu",
"url": "https://questionsmedicales.fr/author/Hui%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Department of Experimental Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, 710038, Shanxi, China."
}
},
{
"@type": "Person",
"name": "Daniel Rifkin",
"url": "https://questionsmedicales.fr/author/Daniel%20Rifkin",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell Biology, NYU Grossman School of Medicine, New York, New York, USA."
}
},
{
"@type": "Person",
"name": "Karan Singh",
"url": "https://questionsmedicales.fr/author/Karan%20Singh",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell Biology, NYU Grossman School of Medicine, New York, New York, USA."
}
},
{
"@type": "Person",
"name": "Hong-Lian Wang",
"url": "https://questionsmedicales.fr/author/Hong-Lian%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Research Center for Integrative Medicine, The Affiliated Traditional Medicine Hospital of Southwest Medical University, Luzhou 646000, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Investigation of mutation load and rate in androgenic mutant lines of rapeseed in early generations evaluated by high-density SNP genotyping.",
"datePublished": "2023-03-02",
"url": "https://questionsmedicales.fr/article/36923873",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.heliyon.2023.e14065"
}
},
{
"@type": "ScholarlyArticle",
"name": "Size-controllable colloidal Ag nano-aggregates with long-time SERS detection window for on-line high-throughput detection.",
"datePublished": "2023-02-17",
"url": "https://questionsmedicales.fr/article/36821962",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.talanta.2023.124358"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of the K-line in patients with ossification of the posterior longitudinal ligament: Analysis of sagittal cervical curvature changes and surgical outcomes.",
"datePublished": "2023-02-15",
"url": "https://questionsmedicales.fr/article/36874452",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fsurg.2023.1095391"
}
},
{
"@type": "ScholarlyArticle",
"name": "Agranulocytosis Secondary to Cancer Chemotherapy Associated With Higher In-Hospital Mortality in Patients With Central Line Insertion During a Hospital Stay.",
"datePublished": "2023-02-07",
"url": "https://questionsmedicales.fr/article/36909119",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7759/cureus.34717"
}
},
{
"@type": "ScholarlyArticle",
"name": "Levetiracetam as a first-line antiseizure medication in WHO grade 2 glioma: Time to seizure freedom and rates of treatment failure.",
"datePublished": "2023-01-23",
"url": "https://questionsmedicales.fr/article/36636895",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/epi.17508"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Scléroprotéines",
"item": "https://questionsmedicales.fr/mesh/D012596"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines de la matrice extracellulaire",
"item": "https://questionsmedicales.fr/mesh/D016326"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines de liaison au TGF-bêta latent",
"item": "https://questionsmedicales.fr/mesh/D053779"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines de liaison au TGF-bêta latent - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines de liaison au TGF-bêta latent",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéines de liaison au TGF-bêta latent",
"description": "Comment diagnostiquer une anomalie des protéines de liaison au TGF-bêta ?\nQuels tests sont utilisés pour évaluer le TGF-bêta ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels symptômes peuvent indiquer un problème avec le TGF-bêta ?\nY a-t-il des marqueurs spécifiques pour ces protéines ?",
"url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cell+Line&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéines de liaison au TGF-bêta latent",
"description": "Quels symptômes sont associés à une dysfonction du TGF-bêta ?\nLa douleur est-elle un symptôme courant ?\nPeut-on observer des anomalies cutanées ?\nLes troubles respiratoires sont-ils liés au TGF-bêta ?\nY a-t-il des signes d'inflammation systémique ?",
"url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cell+Line&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéines de liaison au TGF-bêta latent",
"description": "Comment prévenir les troubles liés au TGF-bêta ?\nY a-t-il des mesures spécifiques à prendre ?\nLes vaccinations sont-elles importantes ?\nL'éducation des patients est-elle cruciale ?\nLe suivi médical régulier est-il recommandé ?",
"url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cell+Line&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéines de liaison au TGF-bêta latent",
"description": "Quels traitements sont disponibles pour les troubles liés au TGF-bêta ?\nLa thérapie génique est-elle une option ?\nLes corticostéroïdes sont-ils utilisés ?\nY a-t-il des traitements expérimentaux ?\nLes changements de mode de vie peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cell+Line&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéines de liaison au TGF-bêta latent",
"description": "Quelles complications peuvent survenir ?\nLes complications cardiovasculaires sont-elles possibles ?\nY a-t-il un risque accru de cancer ?\nLes troubles neurologiques peuvent-ils être liés ?\nComment gérer les complications ?",
"url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cell+Line&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéines de liaison au TGF-bêta latent",
"description": "Quels sont les principaux facteurs de risque ?\nLe vieillissement est-il un facteur de risque ?\nL'obésité influence-t-elle le risque ?\nLe stress a-t-il un impact ?\nLes infections peuvent-elles être un facteur ?",
"url": "https://questionsmedicales.fr/mesh/D053779?mesh_terms=Cell+Line&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des protéines de liaison au TGF-bêta ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins et des analyses génétiques pour détecter des mutations."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer le TGF-bêta ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dosages immunologiques et des tests ELISA sont couramment utilisés pour mesurer le TGF-bêta."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biopsies peuvent être effectuées pour évaluer les tissus affectés et la présence de TGF-bêta."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec le TGF-bêta ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'inflammation chronique ou des troubles de cicatrisation peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour ces protéines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des marqueurs comme le TGF-bêta actif peuvent être utilisés pour évaluer leur fonction."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à une dysfonction du TGF-bêta ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles immunitaires, des fibroses et des anomalies de cicatrisation."
}
},
{
"@type": "Question",
"name": "La douleur est-elle un symptôme courant ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs peuvent survenir en raison d'inflammation ou de fibrose tissulaire."
}
},
{
"@type": "Question",
"name": "Peut-on observer des anomalies cutanées ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies cutanées comme des cicatrices hypertrophiques peuvent se produire."
}
},
{
"@type": "Question",
"name": "Les troubles respiratoires sont-ils liés au TGF-bêta ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles respiratoires peuvent survenir en raison de fibrose pulmonaire associée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes d'inflammation systémique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des signes comme la fièvre et la fatigue peuvent indiquer une inflammation systémique."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés au TGF-bêta ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un mode de vie sain et la gestion des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures spécifiques à prendre ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabac et l'alcool peut réduire le risque de complications liées au TGF-bêta."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent aider à prévenir les infections qui exacerbent les troubles."
}
},
{
"@type": "Question",
"name": "L'éducation des patients est-elle cruciale ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer les patients sur les symptômes et les facteurs de risque est essentiel."
}
},
{
"@type": "Question",
"name": "Le suivi médical régulier est-il recommandé ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical régulier permet de détecter précocement les anomalies."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles liés au TGF-bêta ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments anti-inflammatoires et des thérapies ciblées."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique est explorée pour corriger des anomalies génétiques liées au TGF-bêta."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent être prescrits pour réduire l'inflammation associée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements expérimentaux, comme les inhibiteurs de TGF-bêta, sont en cours d'évaluation."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie peuvent-ils aider ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements comme une alimentation saine et l'exercice peuvent améliorer les symptômes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des fibroses, des troubles respiratoires et des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les complications cardiovasculaires sont-elles possibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications cardiovasculaires peuvent survenir en raison d'une inflammation chronique."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études suggèrent un lien entre TGF-bêta et certains types de cancer."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques peuvent-ils être liés ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent être associés à des déséquilibres du TGF-bêta."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies auto-immunes et l'exposition à des toxines."
}
},
{
"@type": "Question",
"name": "Le vieillissement est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut augmenter le risque de dysfonction des protéines de liaison au TGF-bêta."
}
},
{
"@type": "Question",
"name": "L'obésité influence-t-elle le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité est associée à une inflammation chronique, augmentant le risque de troubles."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut exacerber les troubles liés au TGF-bêta."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles être un facteur ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent déclencher des réponses inflammatoires affectant le TGF-bêta."
}
}
]
}
]
}
Making metal nanoparticle aggregates is a common way to improve surface-enhanced Raman scattering (SERS) enhancement via the formation of hot spots between nanoparticles. Here, we propose a "freeze-th...
This study aimed to investigate the relationship of the K-line with sagittal cervical curvature changes and surgical outcomes in patients with cervical ossification of the posterior longitudinal ligam...
We retrospectively reviewed 84 patients with OPLL who underwent posterior cervical single-door laminoplasty. The patients were divided into a K-line-positive (+) group and a K-line-negative (-) group....
Of 84 total patients, 50 patients were in the K (+) group and 29 patients were in the K (-) group. Neurological function improved in both groups after laminoplasty. The C2-7 Cobb angle, T1 slope, and ...
Neurological function was recovered in both groups, and the clinical effect on the K (+) group was better than that on the K (-) group. The cervical curvature in patients with OPLL tends to be antever...
Background Agranulocytosis secondary to cancer chemotherapy (ASCC) remains a leading cause of morbidity and mortality. Central line-associated bloodstream infections (CLABSI) are also particularly pre...
The high seizure burden seen in World Health Association (WHO) grade 2 gliomas is well documented. This study aims to identify factors that influence the probability of seizure freedom (12 months of s...
This is a retrospective observational analysis of patients from a regional UK neurosurgical center with histologically proven (n = 146) WHO grade 2 glioma and brain tumor related epilepsy. Statistical...
Treatment with levetiracetam as a first-line ASM resulted in a significant increase in the probability of seizure freedom (p < .05) at 2 years compared with treatment with an alternative ASM. Individu...
More than two-thirds of patients with WHO grade 2 glioma related epilepsy treated with levetiracetam first line achieve seizure freedom within 2 years and it is a reasonable first-choice agent. Experi...
Prevention of hazardous drug exposure is essential in averting unnecessary health risks to health care workers (HCW). To address the risk to HCWs when handling hazardous drugs, engineering controls ca...
We aimed to assess the degree to which the American Academy of Pediatrics' (AAP) clinical guidelines were followed when treating attention deficit/hyperactivity disorder (ADHD) in preschoolers....
Using Medicaid claims for children 4 to 5 years of age receiving their first dose of stimulants/alpha-2 agonists in 2017 (...
More than half the sample did not receive first-line BH, which did not differ by demographics. Those receiving BH prior to medication had a higher rate of receiving an ADHD diagnosis. Only three diagn...
More than half the sample did not, conservatively, meet the AAP clinical recommendations. Further research is needed to identify targets for intervention. Limitations are noted....
In this study, forecasting the number of immigrants on the Turkey's maritime line for use in a national security project carried out by Turkish Government within the scope of fight against uncontrolle...
Glaucous (811, L35, and RXL10) and non-glaucous (811bw, L35bw, and RXL10bw) near-isogenic lines (NILs) of rye (Secale cereale L.) forming three pairs of inbred lines were the subject of the research. ...
To assess the impact of initial specimen diversion device (ISDD) on inpatient and emergency department blood culture contamination (BCC), central-line-associated bloodstream infection (CLABSI) standar...
Single-center quasi-experimental prospective cohort study wherein phlebotomists used traditional venipuncture with or without the ISDD while registered nurses (RNs) used traditional venipuncture....
BCC events among phlebotomists and RNs were observed and compared from March 17, 2019, through January 21, 2020, defined by contaminant detection in 1 of 4 bottles for matched sets or 1 of 2 bottles i...
Overall, 24% of blood cultures obtained were from patients in intensive care. Phlebotomists using traditional venipuncture (n = 4,759) had a 2.3% BCC rate; phlebotomists using the ISDD (n = 11,202) ha...
ISDD use by phlebotomists was associated with BCC reduction and reduced false-positive CLABSI results. This patient-care quality improvement could constitute sustainable antibiotic stewardship expansi...